Literature DB >> 33111425

Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.

Kyoko Yamashita1,2, Kenichi Kohashi3, Yuichi Yamada3, Shinya Akatsuka2, Kunihiro Ikuta4,5, Yoshihiro Nishida4,6, Shinya Toyokuni2, Yoshinao Oda3.   

Abstract

Dedifferentiated liposarcoma (DDLPS) is a relatively common soft tissue sarcoma that results from the progression of well-differentiated liposarcoma (WDLPS). This study aimed to investigate the progression process and to clarify the pathological and genetic factors related to poor prognosis in DDLPS. In 32 DDLPS cases and five WDLPS cases, genetic factors were analyzed by custom comparative genomic hybridization (CGH) array, which was designed to densely cover gene regions known to be frequently amplified in WD/DDLPS. The analyses comparing primary and metastatic lesions and those comparing histologically different areas in the same tumor revealed intra-tumoral genetic heterogeneity and progression. According to a prognostic analysis comparing the good-prognosis and the poor-prognosis groups, we selected MDM2 and HMGA2 as candidate genes associated with poor and good prognosis, respectively. The ratios of the amplification or gain levels of MDM2 and HMGA2 expressed in log ratios (log[MDM2/HMGA2] = log[MDM2]-log[HMGA2]) were significantly associated with prognosis. An amplification or gain level of MDM2 that was more than twice that of HMGA2 (MDM2/HMGA2 > 2, log[MDM2/HMGA2] > 1) was strongly related to poor OS (P < .001) and poor distant metastasis-free survival (DMFS) (P < .001). In the pathological analysis of 44 cases of DDLPS, histological tumor grade, cellular atypia, and MDM2 immunoreactivity were related to overall survival (OS), while HMGA2 immunoreactivity tended to be associated with OS. Cellular atypia was also associated with DMFS. In conclusion, histological grade and MDM2 expression were determined to be prognostically important, and the MDM2/HMGA2 amplification or gain ratio was found to have significant prognostic value by the custom CGH array analysis.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  HMGA2; MDM2; MDM2/HMGA2; custom array; dedifferentiated liposarcoma; prognosis

Year:  2020        PMID: 33111425     DOI: 10.1002/gcc.22899

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

Review 1.  Dedifferentiated liposarcoma (DDLPS) in the rectum: A case report.

Authors:  Wei Li; Qi Liu; Yu Mu; Kai Zhang; Tongjun Liu
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

2.  Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.

Authors:  Valentina Zuco; Sandro Pasquali; Silvia Stacchiotti; Nadia Zaffaroni; Monica Tortoreto; Silvia Brich; Stefano Percio; Gian Paolo Dagrada; Chiara Colombo; Roberta Sanfilippo; Calogero Lauricella; Mrinal Gounder; Rihan El Bezawy; Marta Barisella; Angelo Paolo Dei Tos; Paolo Giovanni Casali; Alessandro Gronchi
Journal:  J Exp Clin Cancer Res       Date:  2021-03-01

Review 3.  Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.

Authors:  Giuliana Cassinelli; Sandro Pasquali; Cinzia Lanzi
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

Review 4.  Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions.

Authors:  Liliana Montella; Lucia Altucci; Federica Sarno; Carlo Buonerba; Stefano De Simone; Bianca Arianna Facchini; Elisena Franzese; Ferdinando De Vita; Salvatore Tafuto; Massimiliano Berretta; Gaetano Facchini
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.